TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03939806

Intervention type: DRUG
Intervention: Oxytocin
Description: To be given to Oxytocin group following the clamping of the umbilical cord

Intervention type: DRUG
Intervention: Carbetocin
Description: To be given to Carbetocin group following the clamping of the umbilical cord
Study: NCT01989234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YKP10811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YKP10811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YKP10811

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02632695

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FOOTFIT
Description: Individuals with venous leg ulcers will be instructed on physical activity movements for their lower legs to be performed over six weeks while wearing a foot based activity monitor (accelerometer) that will send them motivational messages and progress reports. For those in the FOOTFIT Plus group, individuals will have the option to communicate with their wound care provider via text messages, emails or phone calls.
Study: NCT04651881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 1
Description: 1 Tab., single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 2
Description: 1 Tab., single oral administration under fed condition
Study: NCT04781114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS002
Description: JS002: 150mg(1mL) Q2W; Placebo 1mL Q2W.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: JS002: 300mg(2mL) Q4W; Placebo 2mL Q4W.
Study: NCT03271775

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy program (group)
Description: Exercises group transmitted by physical therapist (Up to four participant in each group).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy program (computerized exercises)
Description: Remote exercises program accompanied by a physical therapist guidance
Study: NCT02515318

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy program
Description: The physiotherapy treatment will be performed during the hospitalization, every day during 45-60 minutes, and included: breathing exercises, electrostimulation in quadriceps with voluntary contraction and exercises with theraband.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical standard treatment
Description: The standard medical treatment consists on:~Inhaled bronchodilators: Short acting inhaled β2 agonists ( salbutamol and terbutaline) and anticholinergic agents (ipratropium and oxitropium bromide).~Glucocorticoids:~Inhaled glucocorticoids including beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate and triamcinolone acetonide, depending on the expert criteria.~- Antibiotics: The antibiotics were administered according to the GOLD criteria including the β-lactamase inhibitor and fluoroquinolones.
Study: NCT03584633

Intervention type: DRUG
Group type: OTHER
Intervention: Indocyanine Green
Description: The subjects will be exercising on a Nu-Step exercise machine that will exercise their arms and legs simultaneously for five-minute intervals. Every five minutes their limbs will be imaged with an ICG lymphography device to determine the plateau rate of indocyanine green dye after exercise.
Study: NCT04117347

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light therapy A via the Re-Timer®
Description: Subjects will conduct light treatment in the mornings at home.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light therapy B via the Re-Timer®
Description: Subjects will conduct light treatment in the mornings at home.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light therapy C via the Re-Timer®
Description: Subjects will conduct light treatment in the mornings at home.
Study: NCT00780260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: strengths-based case management
Description: 5 session individual strengths-based case management; peer-involvement v. no peer involvement
Study: NCT03120845

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One visit RCT
Description: Root canal treatment in one vist

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post operative pain in two-visits RCT
Description: Root canal treatment in Two visits
Study: NCT04329767

Intervention type: DEVICE
Intervention: IRIS 1.0
Description: Intuitive's IRIS 1.0 system is a software only device and service intended to create and deliver segmented image studies (3D anatomical models) based on patients computed tomography (CT) scans. It is intended as software for preoperative surgical planning, and as software for the intraoperative display of the aforementioned multidimensional digital images.
Study: NCT04312022

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Berry extract
Description: Berry extract supplement (hawthorn berry extract, tart cherry extract, bromelain)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (flour capsule)
Study: NCT02850341

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pedometer
Description: Patients receive a pedometer with instructions how to raise their number of daily steps
Study: NCT00714948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine and cisplatin plus sorafenib
Description: Gemcitabine 1000 mg/m 2 will be administered on days 1 and 8 and cisplatin 35 mg/m 2 will be administered on days 1 and 8. A total of six cycles of therapy will be administered at 21day intervals. Sorafenib 400 mg PO twice daily will be initiated on day 1 of cycle 1 and continued, as tolerated, until the time of disease progression or a maximum of 12 months. The total chemotherapy dose for gemcitabine and cisplatin (GC) may be modified for patients with severe obesity (e.g. body surface area (BSA) \> 2.1), after consultation with the Principal Investigator.
Study: NCT02709161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real-time fMRI neurofeedback: Amygdala
Description: Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
Study: NCT00780260

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: strengths-based case management
Description: 5 session individual strengths-based case management; peer-involvement v. no peer involvement
Study: NCT01355159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid 4 mg
Description: Folic Acid 1.0 mg or placebo x 4 tablets will be taken daily by oral administration. The majority of women in the study will routinely take 1.0 mg folic acid in a prenatal vitamin supplement, as recommended by their primary obstetrical provider; the study requirements do not require that participants change their practice. Therefore the actual total daily dose may be up to 5.1 mg of folic acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo x 4 tablets will be taken daily by oral administration.
Study: NCT03964519

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute changes
Description: In a crossover design, participants will be randomized to perform on Day 1, 3 sets of repetitions (depending on each treatment group) at 70% or 1RM in the full squat exercise. 48-h later, same will be performed but in the contrary crossover arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute changes
Description: In a crossover design, participants will be randomized to perform on Day 1, 3 sets of repetitions (depending on each treatment group) at 70% or 1RM in the full squat exercise. 48-h later, same will be performed but in the contrary crossover arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chronic changes
Description: In a randomized control trial, participants will train during 6 weeks the full squat exercise, 2 days in the week (minimum between-days rest of 48h). Intensity will vary from 70% to 85 of 1RM, and training volume from 3 to 6 sets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chronic changes
Description: In a randomized control trial, participants will train during 6 weeks the full squat exercise, 2 days in the week (minimum between-days rest of 48h). Intensity will vary from 70% to 85 of 1RM, and training volume from 3 to 6 sets.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Chronic changes
Description: In a randomized control trial, participants will train during 6 weeks the full squat exercise, 2 days in the week (minimum between-days rest of 48h). Intensity will vary from 70% to 85 of 1RM, and training volume from 3 to 6 sets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Familiarization
Description: Prior to any intervention, all participants will perform a familiarization of the exercise session, together with a progressive resistance test to estimate the 1 RM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Familiarization
Description: Prior to any intervention, all participants will perform a familiarization of the exercise session, together with a progressive resistance test to estimate the 1 RM

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Familiarization
Description: Prior to any intervention, all participants will perform a familiarization of the exercise session, together with a progressive resistance test to estimate the 1 RM
Study: NCT02606526

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG at birth
Description: See previous description

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Control arm: Delayed BCG
Description: See previous description
Study: NCT00854802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 025
Description: Debio 025 supplied in soft gel capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 025
Description: Debio 025 supplied in soft gel capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 025
Description: Debio 025 supplied in soft gel capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFNα2a
Description: Peg-IFNα2a supplied in pre-filled syringes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFNα2a
Description: Peg-IFNα2a supplied in pre-filled syringes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFNα2a
Description: Peg-IFNα2a supplied in pre-filled syringes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peg-IFNα2a
Description: Peg-IFNα2a supplied in pre-filled syringes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin supplied in tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin supplied in tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin supplied in tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin supplied in tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Debio 025 placebo
Description: Debio 025 placebo supplied in soft gel capsules
Study: NCT01051180

Intervention type: PROCEDURE
Intervention: HALO
Description: Ligation of haemorrhoidal arteries

Intervention type: PROCEDURE
Intervention: HALO
Description: Ligation of haemorrhoidal arteries
Study: NCT00754442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Teriparatide will be given by continuous intravenous infusion at a rate of 12 pmol/kg/hr for 8 hours to both patients and controls

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: Teriparatide will be given by continuous intravenous infusion at a rate of 12 pmol/kg/hr for 8 hours to both patients and controls
Study: NCT01976455

Intervention type: OTHER
Intervention: 20% fewer calories

Intervention type: OTHER
Intervention: 20% fewer calories

Intervention type: OTHER
Intervention: 40% fewer calories

Intervention type: OTHER
Intervention: 40% fewer calories
Study: NCT02715219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asthma Education Programme
Description: The Asthma Education Programme consists of four items. 1. Education video for Asthmatic patient adapted from Info Sehat by Bahagian Pendidikan Kesihatan Kementerian Kesihatan Malaysia which is explaining about Asthma disease, medication and patient responsibility in Asthma management. 2. Small group discussion with subject's to help them understand better in Asthma management. 3. Face to face demonstration and teaching of inhaler technique by three trained nurse in small group range of two to five subjects. At the end of the AEP subject will received a 4. Pamphlet will be obtain from Patients' Education Unit in Ampang Hospital containing vital information about Asthma disease and management. The intervention estimated will take 1 hour to 1 hour 30 minutes to be completed.
Study: NCT03693534

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Pregnancy Rate
Description: The Clinical Pregnancy, Live Birth Rate and Blastulation Rate according to the protocol of COS

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Pregnancy Rate
Description: The Clinical Pregnancy, Live Birth Rate and Blastulation Rate according to the protocol of COS
Study: NCT04645979

Intervention type: OTHER
Intervention: Online survey
Description: Participants will be invited to complete an online questionnaire about their experience of product use.
Study: NCT04026373

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: modified Prolonged Exposure

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: May include consult to health psychology and any follow-up deemed appropriate
Study: NCT00711841

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dexamethasone
Description: Dexamethasone, 10mg (2mL), intravenous, every 12 hours, for 48 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution, 2 mL, intravenous, every 12 hours, for 48 hours
Study: NCT04651881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 2
Description: 1 Tab., single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 2
Description: 1 Tab., single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 2
Description: 1 Tab., single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 2
Description: 1 Tab., single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 2
Description: 1 Tab., single oral administration under fed condition
Study: NCT00211913

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate
Description: single IM dose totalling 200 mcg of conjugate

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single IM dose
Study: NCT00006505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islet Transplantation
Description: Islet cell transplantation. This study will test whether a new islet transplant procedure will enable patients with type 1 diabetes mellitus to stop insulin therapy
Study: NCT02320123

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational DVD
Description: African American patients and their primary non-professional caregivers will watch a DVD created to introduce end-of-life care planning to African Americans receiving palliative care.
Study: NCT04293705

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Teen On-line Problem Solving
Description: The TOPS program is a web-based platform delivered on computers and tablets, which is composed of different self-guided, online sessions on different contents: executive functions, social skills, behavioral strategies, injury-related issues and health and wellness. The TOPS program has been designed to be performed by patients and their families at home. Biweekly Google Meet videoconferences between a coach with expertise in cognitive-behavioral psychotherapy and patients are scheduled along the entire duration of the program.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Teen On-line Problem Solving
Description: The TOPS program is a web-based platform delivered on computers and tablets, which is composed of different self-guided, online sessions on different contents: executive functions, social skills, behavioral strategies, injury-related issues and health and wellness. The TOPS program has been designed to be performed by patients and their families at home. Biweekly Google Meet videoconferences between a coach with expertise in cognitive-behavioral psychotherapy and patients are scheduled along the entire duration of the program.
Study: NCT02278393

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1-Fermented Dairy Product with Phytosterols (test)
Description: 1- 3 bottles of test product/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 2-Fermented dairy Product with No Phytosterols (control)
Description: 2-3 bottles of control product/day
Study: NCT03153735

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CMDHA0101
Description: Maximum injection dose : 22 ml

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PowerFill®
Description: Maximum injection dose : 22 ml
Study: NCT03579953

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real cTBS
Description: This will be delivered with the Magventure Magpro system; 3600 pulses with the active sham coil (double blinded using the USB key).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham cTBS
Description: This will be delivered with the sham Magventure Magpro system; 3600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
Study: NCT01263691

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BioThrax
Description: BioThrax

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV7909 Formulation 1
Description: AV7909 Formulation 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV7909 Formulation 2
Description: AV7909 Formulation 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV7909 Formulation 3
Description: AV7909 Formulation 3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV7909 Formulation 4
Description: AV7909 Formulation 4

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Saline control
Study: NCT03990519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-26366821
Description: Participants will receive sterile solution of JNJ-26366821 subcutaneously (SC).
Study: NCT01681472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6R-MTHF (arfolitixorin) 200 mg/m2
Description: i.v. bolus injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levoleucovorin 200 mg/m2
Description: i.v. bolus injection
Study: NCT03990519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-26366821
Description: Participants will receive sterile solution of JNJ-26366821 subcutaneously (SC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-26366821
Description: Participants will receive sterile solution of JNJ-26366821 subcutaneously (SC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive sodium chloride injection as placebo on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive sodium chloride injection as placebo on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive sodium chloride injection as placebo on Day 1.
Study: NCT03319615

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary energy restriction
Study: NCT01188564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhC1INH
Description: One i.v. injection of rhC1INH at the dose of 50 U/kg, for patients up to 84 kg; one i.v. injection of rhC1INH at the dose of 4200U (2 vials) for patients of 84 kg body weight or greater.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Saline)
Description: One i.v. injection of saline (NaCl 0.9% w/v), equivalent in volume to the active treatment
Study: NCT00711841

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: dexamethasone, 10mg, 2 mL, intravenous solution, every 12 hours , for 48 hours
Study: NCT01681472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6R-MTHF (arfolitixorin) 60 mg/m2
Description: i.v. bolus injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levoleucovorin 60 mg/m2
Description: i.v. bolus injection
Study: NCT03893734

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methadone
Description: Patients in the methadone group will receive a syringe of methadone at induction of anesthesia and a syringe of saline at the end of anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydromorphone
Description: Patients in the hydromorphone group will receive a syringe of saline at induction of anesthesia and a syringe of hydromorphone at the end of anesthesia
Study: NCT02433119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROSARTAN® 5/160mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CODIOVAN® 160/12.5mg
Study: NCT02709161

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: real-time fMRI neurofeedback: HIPS
Description: Participants are shown activity from their left horizontal segment of the intraparietal sulcus in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
Study: NCT04531917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education
Description: Pain Neuroscience Education (PNE) teaches patients about complex pain mechanisms known to be of importance in pain following breast cancer such as malfunctioning of the endogenous analgesic system and pain memories.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioural Graded Activity
Description: Patients in the experimental group will receive a behavioural treatment integrated within the concepts of operant conditioning. The purpose of Behavioural Graded Activity (BGA) is to increase the level of physical activity in the patient's daily lives in a time-contingent manner. On top of that, a healthy behaviour will be positively reinforced to consequently create a withdrawal of the attention towards pain behaviour, which is seen as an unreliable alarm sign in chronic pain patients. The implementation of BGA after PNE is described in the guideline reported by the International Association for the Study of Pain.
Study: NCT03135652

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: adjuvant SBRT
Description: adjuvant SBRT of liver lesions